Etanercept treatment in XXXX : the Polish registry.

@entity1 @entity1499 @entity4932
BACKGROUND: To evaluate the long-term safety and efficacy of etanercept treatment in Polish @entity1 with @entity4932 ( @entity4932 ). MATERIAL/METHODS: The study involved @entity1 , fulfilling the @entity4932 criteria of the International League of Associations of Rheumatology (ILAR), who were started on etanercept therapy after @entity1499 and other synthetic disease-modifying antirheumatic drugs (DMARDs) had proven ineffective. @entity1 data were collected in an electronic registry. Disease improvement was assessed based on Giannini's criteria. RESULTS: The statistical analysis involved 188 @entity1 . Significant improvement was observed in all clinical and laboratory parameters after the first month of therapy and was maintained in the following months. ACR Pediatric 30, 50, 70, 90, and 100 improvement was observed in 81.4%, 65.9%, 27.5%, 16.2%, and 15%, respectively, of @entity1 after 3 months and in 94.7%, 88.4%, 62.1%, 34.7%, and 26.3%, respectively, after 24 months of treatment. Throughout the 72-month safety observation period, 1162 adverse events were reported; the exposure-adjusted AE rate was 2.96 per @entity1 per year. CONCLUSIONS: In @entity1 with various subtypes of @entity4932 resistant to conventional DMARD treatment, etanercept resulted in significant and long-lasting improvements in disease activity. Combination treatment with etanercept and a DMARD was well tolerated.
